Document Detail

Oesophageal varices in cirrhotic patients: from variceal screening to primary prophylaxis of the first oesophageal variceal bleeding.
MedLine Citation:
PMID:  20946450     Owner:  NLM     Status:  MEDLINE    
Bleeding from oesophageal varices is still a lethal complication in cirrhotic patients with portal hypertension. Approximately 5-10% of patients with cirrhosis will develop oesophageal varices per year, and about 25-30% of cirrhotic patients with oesophageal varices and without previous variceal haemorrhage will bleed from ruptured varices. To date, data on preventing the formation/growth of oesophageal varices (preprimary prophylaxis) are conflicting, with insufficient evidence to use β-blockers. There is evidence for the need for primary prophylaxis, and both β-blockers and endoscopic variceal ligation have shown the same efficacy in preventing first bleeding, but which one to prefer is still controversial. The present article reviews the established and potential therapeutic strategies for preventing the development and rupture of oesophageal varices.
Chunqing Zhang; Dominique Thabut; Patrick S Kamath; Vijay H Shah
Publication Detail:
Type:  Journal Article; Review     Date:  2010-10-14
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  31     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-06     Completed Date:  2011-03-21     Revised Date:  2014-09-14    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  108-19     Citation Subset:  IM    
Copyright Information:
© 2010 John Wiley & Sons A/S.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / adverse effects,  therapeutic use*
Endoscopy, Gastrointestinal* / adverse effects
Esophageal and Gastric Varices / diagnosis,  etiology,  physiopathology,  therapy*
Gastrointestinal Hemorrhage / etiology,  physiopathology,  prevention & control*
Hypertension, Portal / etiology*,  physiopathology
Liver Cirrhosis / complications*,  physiopathology
Mass Screening* / methods
Risk Factors
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Adrenergic beta-Antagonists

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Estimation of disease severity in the NHS cervical screening programme. Part II: quantitative method...
Next Document:  A review of abdominal organ transplantation in cystic fibrosis.